Directorate Change

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that Dr Michael Albin, one of the Group’s Non-Executive Directors will be stepping down from the Board with effect from 30 March 2018.

Dr Alastair Smith, Group Chief Executive Officer, commented:
“I would like to thank Michael for his contribution to the Group over the last four years, his advice and support around the development of our Affimer technology has been invaluable. I am glad that Michael’s association with Avacta will continue in an advisory capacity.”